Genaera Corp fka GENR

[surf1944]

Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
Wednesday January 23, 8:00 am ET
- Second filing provides opportunity for additional indications and increased potential market -


PLYMOUTH MEETING, Pa., Jan. 23 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today announced that the investigational new drug (IND) application submitted to the US Food and Drug Administration (FDA) for trodusquemine (MSI-1436) in type 2 diabetes is now in effect. This application represents the second IND filed by the Company in 2007 for MSI- 1436. A previous IND for the treatment of obesity, under which Genaera is currently conducting phase 1 clinical trials, has been in effect since April 2007. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which acts by regulating insulin and leptin receptor signaling through inhibition of the tyrosine phosphatase, PTP-1B.

http://biz.yahoo.com/prnews/080123/nyw032.html?.v=101